Satellos Bioscience Inc. Insider Trading

Satellos Bioscience Inc. is a clinical-stage drug development company based in Canada that operates across Canada, the United States, and Australia. The company focuses on restoring natural muscle repair and regeneration in people affected by degenerative muscle diseases. To support its research, Satellos uses a proprietary discovery platform called MyoReGenX, an automated microscopy system designed to replicate the muscle stem cell environment outside the body. The company is developing SAT-3247, an oral small molecule drug candidate intended for the treatment of Duchenne muscular dystrophy. Satellos holds a license agreement with the Ottawa Hospital Research Institute and an option agreement with the University of British Columbia. The company operates within the biotechnology industry under the broader healthcare sector.